Key result
Novel SCN5A coding and 3'UTR microRNA-binding variants show discordant segregation in Brugada syndrome.
Why the study?
Routine genetic testing in Brugada syndrome typically sequences only protein-coding and flanking intronic regions of SCN5A, excluding the 5'UTR and 3'UTR.
Do coding and non-coding genetic variants in SCN5A and its regulatory microRNAs cosegregate with or functionally contribute to Brugada syndrome onset in an affected Tunisian family?
Observational
No
Do coding and non-coding genetic variants in SCN5A and its regulatory microRNAs cosegregate with or functionally contribute to Brugada syndrome onset in an affected Tunisian family?
This study demonstrates that Brugada syndrome onset and prognosis in an affected family are likely driven by an additive combination of coding and non-coding SCN5A variants affecting microRNA-target interactions (such as miR-1270 and miR-219a) rather than a single causative mutation.
Answers are grounded in this paper and cite their sources.
May support additive SCN5A variant effects in Brugada families; leaves open validation for risk stratification.
BACKGROUND: Brugada syndrome (BrS) is a rare inherited cardiac arrhythmia associated with a high risk of sudden cardiac death (SCD) due to ventricular fibrillation (VF). BrS is characterized by coved-type ST-segment elevation in the right precordial leads (V1-V3). Mutations in SCN5A gene coding for the α-subunit of the NaV1.5 cardiac sodium channel are identified in 15-30% of BrS cases. Genetic testing of BrS patients generally involves sequencing of the protein-coding portions and flanking intronic regions of SCN5A. This excludes the 5'UTR and 3'UTR from the routine genetic testing. METHODS: We here screened the coding sequence, the flanking intronic regions as well as the 5' and 3'UTR regions of SCN5A gene and further five candidate genes (GPD1L, SCN1B, KCNE3, SCN4B, and MOG1) in a Tunisian family diagnosed with BrS. RESULTS: A new SCN5A-Q1000K mutation was identified along with two common polymorphisms (H558R and D1819). Multiple genetic variants were identified on the SCN5A 3'UTR, one of which is predicted to create additional microRNA binding site for miR-1270. Additionally, we identified the hsa-miR-219a-rs107822. No relevant coding sequence variant was identified in the remaining studied candidate genes. CONCLUSIONS: The absence of genotype-phenotype concordance within all the identified genetic variants in this family gives extra evidences about the complexity of the disease and suggests that the occurrence and prognosis of BrS is most likely controlled by a combination of multiple genetic factors, rather than a single variant. Most SCN5A variants were localized in non-coding regions hypothesizing an impact on the miRNA-target complementarities.
No takes yet. Share an insight, caveat, or question.
Daimi et al. (2019) conducted an observational in Brugada syndrome (BrS). Genetic screening of SCN5A (coding, flanking intronic, 5'UTR, and 3'UTR regions), candidate genes (GPD1L, SCN1B, KCNE3, SCN4B, MOG1), and microRNAs, plus in vitro miR-1270 overexpression vs. 100 ethnically matched healthy Tunisian controls without cardiac defects; non-transfected or negative control pre-miR transfected cells in vitro was evaluated on Identification of genetic variants in SCN5A and candidate genes, genotype-phenotype concordance, and functional impact of 3'UTR variants on Scn5a mRNA expression via miR-1270 (p=<0.05). Genetic screening in a Brugada syndrome family identified a novel SCN5A-Q1000K mutation and 3'UTR variants creating a miR-1270 binding site that reduces Scn5a expression, without single-variant genotype-phenotype concordance.
Synapse has enriched 10 related papers. Consider them for comparative context: